SyncThink announces the receipt of its 12th patent for its EYE-SYNC technology. US patent 14/530,598 allows SyncThing to use system and methods for creating and changing dynamic content based on eye gaze analysis.
Intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment, according to a recent study.
Rehabilitation technologies can help patients return to walking and an active lifestyle after stroke and other neurological disorders. A feature in the latest issue of Physical Therapy Products magazine.
Scott Anderson, formerly the athletic director at Stanford University, joins SyncThink as chief customer officer. In addition, SyncThink opens a permanent office in Palo Alto, Calif.
Valencia, Calif-based Bioness Inc reports that its L300 Go System, which received FDA clearance in January, has now received the CE Mark in the European Union.
Parker Hannifin Corp announces it has received expanded FDA clearance for its Indego exoskeleton, for people with spinal cord injury (SCI) levels T3 and below in home and community settings.
The cost of prescriptions for multiple sclerosis (MS) drugs nearly tripled over seven years, and the introduction of a generic version of one of the most common drugs had little overall effect on prices, according to a recent study in Neurology, the medical journal of the American Academy of Neurology.
Music therapy sessions have a positive effect on the neurorehabilitation of acute stroke patients, as well as their mood, according to a recent study.
People with Parkinson's disease who participate in a special, non-contact boxing program may have better quality of life and be more likely to exercise than those who do not participate, according to a recent study.